CIK 0001980845 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
enGene Therapeutics Inc.
Sign in to watch- Ticker
- ENGN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Oct 31
- Incorporated
- Canada (Federal Level)
- Entity type
- operating
- Phone
- (514) 332-4888
- Business address
- 4868 RUE LEVY, SUITE 220, SAINT-LAURENT, Quebec, Canada
- Former names
- enGene Holdings Inc.
Securities
- ENGN Common Stock Nasdaq
- ENGNW Warrants Nasdaq
- DEF 14A Proxy Proxy Statement
- 4 Derivatives Options or other derivatives
- 4 Option exercise Chief Technology Officer acquired 52,940 shares (option exercise)
- 4 Derivatives Options or other derivatives
- 424B3 Offering Prospectus
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- EFFECT Other Notice of Effectiveness
- 424B3 Offering Prospectus
- CORRESP Other Correspondence Between Filers and SEC Staff
- S-8 Other Securities Offered to Employees in Benefit Plans
- S-1/A Offering Registration Statement
- CORRESP Other Correspondence Between Filers and SEC Staff
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 4 Grant or award Director acquired 800,000 shares (grant or award)
- 4 Grant or award 10% owner acquired 800,000 shares (grant or award)
- SC 13D/A Stake Beneficial Ownership Report
Page 10 of 14 · 268 filings